IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase
IceCure Medical, developer of the ProSense® Cryoablation System, announced that CEO Eyal Shamir will present at the A.G.P / Alliance Global Partners' Virtual Healthcare Company Showcase on May 21, 2024. The presentation will cover key achievements, including the completion of the ICE3 breast cancer cryoablation trial, submission of results to the FDA, and a pending De Novo Classification Request for marketing clearance. Additionally, the company will highlight ProSense®'s growing global reach and its efficacy in women's health and interventional oncology. Shamir emphasized the significance of these developments for enhancing shareholder value and accelerating commercial goals in the U.S. market.
- Completion of the ICE3 breast cancer cryoablation trial.
- Published positive top-line results from the ICE3 trial.
- Submission of the complete dataset to the FDA for review.
- Pending De Novo Classification Request with the FDA for ProSense®.
- Increasing global commercial reach of the ProSense® system.
- Growing body of independent research supporting ProSense®'s efficacy and safety.
- Opportunity to enhance shareholder value through strategic presentations and updates.
- Focus on accelerating commercial goals for ProSense® in the U.S. market.
- Pending FDA approval, which carries inherent risks and uncertainties.
- Potential delays in obtaining marketing clearance for ProSense®.
- High dependency on FDA's De Novo Classification Request outcome.
- Unspecified financial impacts from pending regulatory and trial outcomes.
![IceCure Medical Logo IceCure Medical Logo](https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg)
Mr. Shamir will present an update on the latest developments and catalysts for IceCure, including the recently announced results of the ICE3 breast cancer cryoablation trial, its pending De Novo Classification Request with the
"This has already been an incredibly productive year for IceCure Medical as we completed the ICE3 study, published positive top line results and submitted the complete dataset to the FDA last month," commented Eyal Shamir, Chief Executive Officer. "These are exciting developments, and the conference allows us to highlight our achievements and share our vision for the next phase upon a successful outcome with the FDA and enhance shareholder value as we accelerate our commercial goals for ProSense in the U.S. market."
About ProSense®
The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
SOURCE IceCure Medical
FAQ
What is IceCure Medical's latest achievement?
When is IceCure Medical presenting at the A.G.P / Alliance Global Partners' Virtual Healthcare Company Showcase?
What is the significance of the ICE3 trial for IceCure Medical?
What is the ProSense® Cryoablation System?
Why is IceCure Medical's pending De Novo Classification Request important?
How is IceCure Medical expanding its global reach?